REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled Trial

Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.

Manning Jessica E, Oliveira Fabiano, Coutinho-Abreu Iliano V, Herbert Samantha, Meneses Claudio, Kamhawi Shaden, Baus Holly Ann, Han Alison, Czajkowski Lindsay, Rosas Luz Angela
Lancet (London, England)2020DOI: 10.1016/S0140-6736(20)31048-5

Citations

0

Subjects

Non-Human

Study Context

Randomized controlled trials are the gold standard for evaluating treatment efficacy. The randomized design minimizes bias, making findings more reliable for clinical decision-making.

Citation

Manning Jessica E, Oliveira Fabiano, Coutinho-Abreu Iliano V et al.. (2020). Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.. Lancet (London, England). https://doi.org/10.1016/S0140-6736(20)31048-5

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.